Interesting article reinforcing what we already know about big pharma's impending patents cliffs across a wide range of drugs.
IMO it reinforces the RAC strategy not to rush into a deal. As times progresses, and assuming our clinical results confirm the efficancy of bisantrene, the timing for a deal may well be when BP is most desperate to replenish their revenue streams.
https://finance.yahoo.com/news/pharmaceutical-industry-finds-itself-historical-164751287.html?guccounter=1
Interesting article reinforcing what we already know about big...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
-0.025(1.32%) |
Mkt cap ! $317.5M | |||
| Open | High | Low | Value | Volume |
| $1.97 | $2.02 | $1.85 | $1.189M | 605.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 30 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.86 |
Change
-0.025 ( 1.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.97 | $2.04 | $1.86 | 48029 | ||
| Last updated 15.57pm 13/06/2024 ? | |||||
| RAC (ASX) Chart |